Author

Jean Marc Schiano de Collela

Observed names: J M Schiano de Collela, J. Schiano de Collela, J.-M. Schiano de Collela, J.M. Schiano de Collela, Jean-Marc Schiano De Collela, Jean-Marc Schiano de Collela, Jean-Marc Schiano-de Collela

Observed institutions: Inserm, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier Universitaire Amiens-Picardie, Institut Paoli-Calmettes, Institut pour l'avancée des biosciences, Centre Hospitalier de Boulogne sur Mer

OpenAlex ID: A5039679677

Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

2012 · Gandhi Damaj, Rémy Gressin, et al. · Journal of Clinical Oncology · 166

Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma

2011 · Jean El Cheikh, Elias Kfoury, et al. · Hematology/Oncology and Stem Cell Therapy · 41

PDF

A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

2022 · Krish Patel, Peter A. Riedell, et al. · Blood · 38

Features and Risk Factors of Peripheral Neuropathy During Treatment with Bortezomib for Advanced Multiple Myeloma

2008 · Jean El-Cheikh, Anne-Marie Stoppa, et al. · Clinical Lymphoma & Myeloma · 35

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions

2023 · Anaïs Schavgoulidze, Aurore Perrot, et al. · Blood Cancer Journal · 29

PDF

Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution

2013 · Florence Broussais-Guillaumot, Diane Coso, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 15

A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

2006 · D Coso, C Sebban, et al. · Bone Marrow Transplantation · 12

Autologous Stem Cell Transplant in 2nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

2022 · Aude Collignon, Benjamin Bouchacourt, et al. · Blood · 6

Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma

2019 · Guillaume Manson, Pauline Brice, et al. · Blood · 4

Features and Risk Factors of Peripheral Neuropathy during Treatment of Advanced Multiple Myeloma with Bortezomib.

2006 · Jean El-Cheikh, Anne Marie Stoppa, et al. · Blood · 2

OA-68 Teclistamab Plus Talquetamab Consolidation in Newly Diagnosed Myeloma Patients With Positive Measurable Residual Disease After DVRD Induction: Interim Analysis of the Phase 2 Study IFM 2022-01

2026 · Cyrille Touzeau, Aurore Perrot, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

High-Risk Genomic Consensus Model Validation in a Large Cohort of Newly Diagnosed Multiple Myeloma Patients Using Next Generation Sequencing

2025 · Anais Schavgoulidze, Aurore Perrot, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Superiority of Allogenic Stem Cell Transplantation after Anti-PD1 Therapy over Anti-PD1 Monotherapy Alone in Relapse/Refractory Hodgkin Lymphoma: Real World Evidence from the French Early Access Program

2018 · Guillaume Manson, Jean-Baptiste Mear, et al. · Blood · 1

Autologous Stem Cell Transplantation (auto-SCT) in Elderly Patients with Multiple Myeloma (MM): Age per se Does Not Affect Outcome.

2007 · Jean El-Cheikh, Elias Kfoury, et al. · Blood · 1

PA-366 Prognostic Impact of CDKN2C Mutations in Newly Diagnosed Multiple Myeloma Patients

2026 · Anaïs Schavgoulidze, Luka Pavageau, et al. · Clinical Lymphoma Myeloma & Leukemia

Non-Myeloablative Conditioning Regimen before T-Cell Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Advanced Lymphoma

2019 · Catalina Montes De Oca, Thomas Pagliardini, et al. · Blood

A Phase Ii Study of Lenalidomide and Rituximab (r²) Combination in Patients With High‐risk Refractory/relapsed Diffuse Large B‐cell Lymphoma

2019 · R. Bouabdallah, C. Zemmour, et al. · Hematological Oncology

Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) Registry Data

2018 · Fabien Le Bras, Camille Laurent, et al. · Blood

BEAM as a Frontline High Dose Chemotherapy Supported by Autologous PBSCT in Elderly Patients (≥60 Years) with Diffuse Large B-Cell Lymphoma (DLBCL): Comparison with Younger Cohort of Patients.

2007 · V. Ivanov, D. Coso, et al. · Blood

Good Safety and Tolerance Profiles of Long Term Treatment of Advanced Multiple Myeloma (MM) with Bortezomib.

2007 · Jean El-Cheikh, Anne-Marie Stoppa, et al. · Blood

Traitement par chimiothérapie intensive-rituximabdes LMNH associés à l'infection VIH

2003 · J. Rey, A. Charbonnier, et al. · La Revue de Médecine Interne

Works count: 21

Citation count: 351

H-index: 7

I10-index: 7